Literature DB >> 26271952

The Endocannabinoid System and its Modulation by Phytocannabinoids.

Vincenzo Di Marzo1, Fabiana Piscitelli2.   

Abstract

The endocannabinoid system is currently defined as the ensemble of the two 7-transmembrane-domain and G protein-coupled receptors for Δ(9)-tetrahydrocannabinol (but not for most other plant cannabinoids or phytocannabinoids)-cannabinoid receptor type-1 (CB1R) and cannabinoid receptor type-2 (CB2R); their two most studied endogenous ligands, the "endocannabinoids" N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG); and the enzymes responsible for endocannabinoid metabolism. However, anandamide and 2-AG, and also the phytocannabinoids, have more molecular targets than just CB1R and CB2R. Furthermore, the endocannabinoids, like most other lipid mediators, have more than just one set of biosynthetic and degrading pathways and enzymes, which they often share with "endocannabinoid-like" mediators that may or may not interact with the same proteins as Δ(9)-tetrahydrocannabinol and other phytocannabinoids. In some cases, these degrading pathways and enzymes lead to molecules that are not inactive and instead interact with other receptors. Finally, some of the metabolic enzymes may also participate in the chemical modification of molecules that have very little to do with endocannabinoid and cannabinoid targets. Here, we review the whole world of ligands, receptors, and enzymes, a true "endocannabinoidome", discovered after the cloning of CB1R and CB2R and the identification of anandamide and 2-AG, and its interactions with phytocannabinoids.

Entities:  

Keywords:  Endocannabinoidome; Endocannabinoids; Phytocannabinoids; TRP channels

Mesh:

Substances:

Year:  2015        PMID: 26271952      PMCID: PMC4604172          DOI: 10.1007/s13311-015-0374-6

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  55 in total

1.  Activation of GPR18 by cannabinoid compounds: a tale of biased agonism.

Authors:  Linda Console-Bram; Eugen Brailoiu; Gabriela Cristina Brailoiu; Haleli Sharir; Mary E Abood
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

2.  Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability.

Authors:  Fabio Arturo Iannotti; Charlotte L Hill; Antonio Leo; Ahlam Alhusaini; Camille Soubrane; Enrico Mazzarella; Emilio Russo; Benjamin J Whalley; Vincenzo Di Marzo; Gary J Stephens
Journal:  ACS Chem Neurosci       Date:  2014-07-29       Impact factor: 4.418

3.  Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.

Authors:  Luciano De Petrocellis; Alessia Ligresti; Aniello Schiano Moriello; Marco Allarà; Tiziana Bisogno; Stefania Petrosino; Colin G Stott; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

4.  Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.

Authors:  V Di Marzo; D Melck; P Orlando; T Bisogno; O Zagoory; M Bifulco; Z Vogel; L De Petrocellis
Journal:  Biochem J       Date:  2001-08-15       Impact factor: 3.857

5.  Characterization of cannabidiol-mediated cytochrome P450 inactivation.

Authors:  L M Bornheim; E T Everhart; J Li; M A Correia
Journal:  Biochem Pharmacol       Date:  1993-03-24       Impact factor: 5.858

Review 6.  Why do cannabinoid receptors have more than one endogenous ligand?

Authors:  Vincenzo Di Marzo; Luciano De Petrocellis
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

7.  Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors.

Authors:  James D Leggett; S Aspley; S R G Beckett; A M D'Antona; D A Kendall; D A Kendall
Journal:  Br J Pharmacol       Date:  2004-01-05       Impact factor: 8.739

8.  Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.

Authors:  J Priller; E M Briley; J Mansouri; W A Devane; K Mackie; C C Felder
Journal:  Mol Pharmacol       Date:  1995-08       Impact factor: 4.436

9.  Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids.

Authors:  Luciano De Petrocellis; Katarzyna Starowicz; Aniello Schiano Moriello; Marta Vivese; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Exp Cell Res       Date:  2007-01-18       Impact factor: 3.905

10.  Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.

Authors:  Ankur Kapur; Pingwei Zhao; Haleli Sharir; Yushi Bai; Marc G Caron; Larry S Barak; Mary E Abood
Journal:  J Biol Chem       Date:  2009-09-01       Impact factor: 5.157

View more
  87 in total

1.  Endocannabinoid regulation in white and brown adipose tissue following thermogenic activation.

Authors:  Lucia M Krott; Fabiana Piscitelli; Markus Heine; Simona Borrino; Ludger Scheja; Cristoforo Silvestri; Joerg Heeren; Vincenzo Di Marzo
Journal:  J Lipid Res       Date:  2016-01-14       Impact factor: 5.922

Review 2.  Cannabinoids in chronic non-cancer pain medicine: moving from the bench to the bedside.

Authors:  H Meng; A Deshpande
Journal:  BJA Educ       Date:  2020-07-21

Review 3.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

4.  The endocannabinoid system in the baboon (Papio spp.) as a complex framework for developmental pharmacology.

Authors:  Iram P Rodriguez-Sanchez; Josee Guindon; Marco Ruiz; M Elizabeth Tejero; Gene Hubbard; Laura E Martinez-de-Villarreal; Hugo A Barrera-Saldaña; Edward J Dick; Anthony G Comuzzie; Natalia E Schlabritz-Loutsevitch
Journal:  Neurotoxicol Teratol       Date:  2016-06-18       Impact factor: 3.763

5.  Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2.

Authors:  William R Arnold; Austin T Weigle; Aditi Das
Journal:  J Inorg Biochem       Date:  2018-04-07       Impact factor: 4.155

Review 6.  Interactions between recreational cannabis use and cognitive function: lessons from functional magnetic resonance imaging.

Authors:  Kelly A Sagar; Staci A Gruber
Journal:  Ann N Y Acad Sci       Date:  2018-11-13       Impact factor: 5.691

7.  Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.

Authors:  Fabio Arturo Iannotti; Ester Pagano; Aniello Schiano Moriello; Filomena Grazia Alvino; Nicolina Cristina Sorrentino; Luca D'Orsi; Elisabetta Gazzerro; Raffaele Capasso; Elvira De Leonibus; Luciano De Petrocellis; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2018-09-09       Impact factor: 8.739

Review 8.  The Role of the Endocannabinoid System in the Brain-Gut Axis.

Authors:  Keith A Sharkey; John W Wiley
Journal:  Gastroenterology       Date:  2016-04-29       Impact factor: 22.682

Review 9.  Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.

Authors:  Dennis J Sholler; Marilyn A Huestis; Benjamin Amendolara; Ryan Vandrey; Ziva D Cooper
Journal:  Pharmacol Biochem Behav       Date:  2020-10-18       Impact factor: 3.533

Review 10.  Anandamide and endocannabinoid system: an attractive therapeutic approach for cardiovascular disease.

Authors:  Virna Margarita Martín Giménez; Sandra Edith Noriega; Diego Enrique Kassuha; Lucía Beatriz Fuentes; Walter Manucha
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.